Atorvastatin Improves the Propionic Acid- Induced Autism in Rats: The Roles of Sphingosine-1-Phosphate and Anti-inflammatory Action

Basit Öğe Kaydı
dc.authoridErbas, Oytun/0000-0001-5427-8428
dc.authoriduyanikgil, Yigit/0000-0002-4016-0522
dc.contributor.authorDurankus, Ferit
dc.contributor.authorBudak, Korkut
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorSever, Ibrahim H.
dc.contributor.authorOzkul, Bahattin
dc.contributor.authorUyanikgil, Yigit
dc.contributor.authorAlbayrak, Neslihan
dc.date.accessioned2024-10-29T17:59:53Z
dc.date.available2024-10-29T17:59:53Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesien_US
dc.description.abstractPurpose The aim of this study is to investigate the benefits of atorvastatin on the propionic acid-induced autism model via increasing sphingosine-1-phosphate and anti-inflammatory actions with imaging and brain tissue investigations. Materials and methods Twenty-five mg/kg/day/rat of propionic acid (PPA) was administered intraperitoneally to 20 male Wistar rats, and 10 male Wistar rats were fed orally. Study groups were designed as follows: Group 1: Control Group (orally fed control, n=10); Group 2 (PPA+saline, n=10); Group 3 (PPA+Atorvastatin, n=10). The brain biochemical and histopathology assessments and magnetic resonance (MR) imaging were conducted across groups in order to compare them. Results The PPA+Atorvastatin group was found to have significantly lower levels of brain malondialdehyde, IL -2 level, IL-17, tumor necrosis factor-alpha (TNF-??), and lactate compared to the PPA+saline group. The PPA+Atorvastatin group had higher levels of nerve growth factor and nuclear factor erythroid 2-related factor 2 (NRF-2) and sphingosine-1-phosphate. In histopathology assessments, the PPA+Atorvastatin group was found to have significantly higher neuronal counts of CA1 and CA2 in the hippocampus, and Purkinje cells in the cerebellum. Conclusions Current findings suggest that atorvastatin increases sphingosine-1-phosphate levels and decreases inflammatory actions which characterize the autism rodent model implemented in this study. These preliminary results have to be confirmed by further experimental and clinical studies.en_US
dc.identifier.doi10.7759/cureus.36870
dc.identifier.issn2168-8184
dc.identifier.issue3en_US
dc.identifier.pmid37123681en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.36870
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14866
dc.identifier.volume15en_US
dc.identifier.wosWOS:000980801400024en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCureus Incen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthippocampusen_US
dc.subjectlactateen_US
dc.subjectsphingosineen_US
dc.subjectatorvastatinen_US
dc.subjectautismen_US
dc.titleAtorvastatin Improves the Propionic Acid- Induced Autism in Rats: The Roles of Sphingosine-1-Phosphate and Anti-inflammatory Actionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu